
Заявка Oncobox в YC
Oncobox прошел Y Combinator в потоке Summer 2017 как компания из сферы Healthcare. Ниже: чем занимается компания, кто ее основал, и ее заявка в YC, реконструированная вопрос за вопросом в реальной форме YC.
- Поток YC
- Summer 2017
- Сфера
- HealthcareDiagnostics
- Размер команды
- 11
- Статус
- Active
- Запущено
- 2017
Фаундеры
Andrew GarazhaFounder/CEO
Anton BuzdinFounder/CSO
Чем занимается Oncobox
Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would most effectively fight individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe and Asia on 900 patients with various late-stage cancers, Oncobox increased the effectiveness of targeted therapies from 25% to 64%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock. They don’t always know which medication will be most effective for their patients. Because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Dx analyses tumor DNA, RNA, and molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We actively seek partners from pharma, hospitals/clinicians, payers, and genomic centers. Feel free to contact us at. Our team and the scientific advisory board consisting of leading scientists and researchers from UCLA, Stanford, Johns Hopkins University, Boston University, Tufts University, and Rutgers University.
Заявка Oncobox в YC, реконструирована
Заявка Y Combinator
Oncobox, батч Summer 2017. Реальные вопросы из анкеты, ответы из публичных данных.
- Founders2
- Company7
- Progress7
- Idea4
- Equity3
- Curious2
- Batch Preference1
Company
Oncobox
Finding the right cancer drug for each patient.
Oncobox analyzes tumor DNA, RNA, and molecular pathways to produce a report that helps oncologists pick the most effective targeted cancer drugs for an individual patient. Our product focuses on late-stage cancer patients, where current targeted therapies only work 25% of the time. Our system increases that effectiveness significantly by identifying the key molecular targets specific to each tumor.
We live in Walnut, CA and would base the company here after YC.
We are already based in Walnut, CA and want to stay here because of access to regional research partners and proximity to biotech clusters in California.
21 еще ответ в полной заявке
Founders, Progress, Idea, Equity, Curious, Batch Preference находятся в полной версии. Создайте бесплатную учетную запись, чтобы открыть ее в YC Insights, рядом с каждым другим потоком YC.
Часто задаваемые вопросы
Это реальная заявка Oncobox в YC?
Нет. Y Combinator держит поданные заявки в приватности. Это реконструкция: реальные вопросы формы YC, ответы на которые основаны на публичных данных Oncobox (заметки о запуске, бэкграунд фаундеров, описание продукта). Это показывает, как компания вроде Oncobox представила бы себя YC, а не текст, который они подали.
В каком потоке YC был Oncobox?
Oncobox был частью потока Y Combinator Summer 2017.
Кто основал Oncobox?
Oncobox был основан Andrew Garazha, Anton Buzdin.
Что делает Oncobox?
Finding the right cancer drug for each patient.
Как мне прочитать полную реконструированную заявку?
Создай бесплатный аккаунт Round Funded. Полная 26-ответная версия заявки Oncobox и каждой другой партии YC доступна в YC Insights.